Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedOpen accessLassaHemorrhagic Fever

Lassa fever and Argentine hemorrhagic fever treatment in guinea pigs using broad-spectrum cap-dependent endonuclease inhibitors

mBio·

Junki Maruyama, Satoshi Taniguchi, Takeshi Saito, Shintaro Yamada, Rachel A. Reyna, Ruchi Paroha, Daiki Kobayashi, Gavriella Siman-Tov, Christine Click, Kirsten Littlefield, Shinsuke Toba, Yoshiyuki Taoda, Misato Shibazaki, Cheng Huang, Michihito Sasaki, Yasuko Orba, Hirofumi Sawa, Akihiko Sato, Slobodan Paessler

DOI
10.1128/mbio.00880-26
PMID
42606356
PMCID
OpenAlex
Study type
Journal article
Publisher
American Society for Microbiology
Article type
journal-article
Integrity
current

Why this research matters now

These viruses trigger severe human hemorrhagic illnesses with substantial mortality and scarce treatment alternatives. The observed cross-reactive antiviral properties indicate potential utility for developing broader therapeutic options.

01

Structured evidence summary

Research question

What is the therapeutic efficacy of cap-dependent endonuclease inhibitors against lethal arenavirus infections in experimental animals?

Study design

Preclinical laboratory evaluation employing guinea pig infection models to assess antiviral compound performance.

Population and setting

Laboratory guinea pigs experimentally challenged with lethal doses of Lassa virus and Argentine hemorrhagic fever virus.

Main findings

The tested inhibitors effectively reduced viral replication and conferred therapeutic survival benefits in the infected animals. Researchers also isolated additional compounds showing activity against multiple other dangerous arenaviruses.

Public-health relevance

These viruses trigger severe human hemorrhagic illnesses with substantial mortality and scarce treatment alternatives. The observed cross-reactive antiviral properties indicate potential utility for developing broader therapeutic options.

Important limitations

The investigation is restricted to preclinical animal experiments and lacks human pharmacokinetic, toxicological, or clinical trial data.

GIDS interpretation

This publication supplies early-stage mechanistic and efficacy data that may guide subsequent pharmaceutical development pathways. It contextualizes a specific molecular target without indicating current field deployment or real-time monitoring relevance.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 8 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseabout diseaseaddresses topicevaluates interventionhas pathogen typestudied instudied population settinguses study design